Salphati L - Search Results

1

Effects of ketoconazole on digoxin absorption and disposition in rat.

Salphati L, Benet LZ. Salphati L, et al. Pharmacology. 1998 Jun;56(6):308-13. doi: 10.1159/000028214. Pharmacology. 1998. PMID: 9654217

2

Variability in the disposition of chlorzoxazone.

de Vries JD, Salphati L, Horie S, Becker CE, Hoener BA. de Vries JD, et al. Among authors: salphati l. Biopharm Drug Dispos. 1994 Oct;15(7):587-97. doi: 10.1002/bdd.2510150706. Biopharm Drug Dispos. 1994. PMID: 7849234 Clinical Trial.

3

Modulation of P-glycoprotein expression by cytochrome P450 3A inducers in male and female rat livers.

Salphati L, Benet LZ. Salphati L, et al. Biochem Pharmacol. 1998 Feb 15;55(4):387-95. doi: 10.1016/s0006-2952(97)00436-x. Biochem Pharmacol. 1998. PMID: 9514072

4

Metabolism of digoxin and digoxigenin digitoxosides in rat liver microsomes: involvement of cytochrome P4503A.

Salphati L, Benet LZ. Salphati L, et al. Xenobiotica. 1999 Feb;29(2):171-85. doi: 10.1080/004982599238722. Xenobiotica. 1999. PMID: 10199593

5

Evaluation of a single-pass intestinal-perfusion method in rat for the prediction of absorption in man.

Salphati L, Childers K, Pan L, Tsutsui K, Takahashi L. Salphati L, et al. J Pharm Pharmacol. 2001 Jul;53(7):1007-13. doi: 10.1211/0022357011776252. J Pharm Pharmacol. 2001. PMID: 11480535

6

In vivo modulation of intestinal CYP3A metabolism by P-glycoprotein: studies using the rat single-pass intestinal perfusion model.

Cummins CL, Salphati L, Reid MJ, Benet LZ. Cummins CL, et al. Among authors: salphati l. J Pharmacol Exp Ther. 2003 Apr;305(1):306-14. doi: 10.1124/jpet.102.044719. J Pharmacol Exp Ther. 2003. PMID: 12649383

7

Preclinical assessment of the absorption and disposition of the phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor GDC-0980 and prediction of its pharmacokinetics and efficacy in human.

Salphati L, Pang J, Plise EG, Lee LB, Olivero AG, Prior WW, Sampath D, Wong S, Zhang X. Salphati L, et al. Drug Metab Dispos. 2012 Sep;40(9):1785-96. doi: 10.1124/dmd.112.046052. Epub 2012 Jun 13. Drug Metab Dispos. 2012. PMID: 22696419

8

PK-PD modeling of combination efficacy effect from administration of the MEK inhibitor GDC-0973 and PI3K inhibitor GDC-0941 in A2058 xenografts.

Choo EF, Ng CM, Berry L, Belvin M, Lewin-Koh N, Merchant M, Salphati L. Choo EF, et al. Among authors: salphati l. Cancer Chemother Pharmacol. 2013 Jan;71(1):133-43. doi: 10.1007/s00280-012-1988-6. Epub 2012 Oct 7. Cancer Chemother Pharmacol. 2013. PMID: 23053270

9

Pharmacokinetics and absorption of the anticancer agents dasatinib and GDC-0941 under various gastric conditions in dogs--reversing the effect of elevated gastric pH with betaine HCl.

Pang J, Dalziel G, Dean B, Ware JA, Salphati L. Pang J, et al. Among authors: salphati l. Mol Pharm. 2013 Nov 4;10(11):4024-31. doi: 10.1021/mp400356m. Epub 2013 Sep 11. Mol Pharm. 2013. PMID: 23980865

10

Impact of food and the proton pump inhibitor rabeprazole on the pharmacokinetics of GDC-0941 in healthy volunteers: bench to bedside investigation of pH-dependent solubility.

Ware JA, Dalziel G, Jin JY, Pellett JD, Smelick GS, West DA, Salphati L, Ding X, Sutton R, Fridyland J, Dresser MJ, Morrisson G, Holden SN. Ware JA, et al. Among authors: salphati l. Mol Pharm. 2013 Nov 4;10(11):4074-81. doi: 10.1021/mp4005595. Epub 2013 Oct 24. Mol Pharm. 2013. PMID: 24099279 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results